Status:

COMPLETED

Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)

Lead Sponsor:

Bioprojet

Conditions:

Narcolepsy With Cataplexy

Excessive Daytime Sleepiness

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Double blind, randomized, parallel groups study of Pitolisant versus placebo, in narcoleptic patients experiencing EDS, and cataplexy (minimum of 3 complete or partial cataplexy attacks per week). Th...

Detailed Description

The treatment period (7 weeks double blind) will aim at demonstrating the efficacy of Pitolisant on the number of cataplexy attacks and the Excessive Daytime Sleepiness by verifying whether the result...

Eligibility Criteria

Inclusion

  • Main
  • Narcoleptic with cataplexy : at least 3 weekly cataplexy attacks
  • ESS \> or = 12
  • ICF signed and dated
  • Main

Exclusion

  • Other conditions that could generate EDS
  • Psychological and neurological disorders
  • Acute or chronic severe disease
  • Treatment by prohibited medication

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2015

Estimated Enrollment :

103 Patients enrolled

Trial Details

Trial ID

NCT01800045

Start Date

April 1 2013

End Date

January 1 2015

Last Update

August 31 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

State Health Center

Budapest, Hungary, 1134

Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) | DecenTrialz